• Oryzon Genomics won a USPTO Notice of Allowance for a U.S. patent application covering iadademstat with gilteritinib in myeloid cancers.
• The patent, once granted, is expected to expire in 2042, excluding any term adjustments or extensions.
• Phase Ib FRIDA data shown at EHA 2026 reported a 67% composite complete remission rate in FLT3-mutated relapsed or refractory AML.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.